Cytrx Corporation
Records under this name other than the patents Cytrx Corporation holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,384,104 | Delivery systems for controlled drug release Formerly held In force · USPTO record | In force | USPTO record | |
| US 12,497,417 | Delivery systems for controlled drug release Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,377,473 | Albumin-Binding Prodrugs of Auristatin E Derivatives Formerly held In force · High confidence | In force | High confidence | |
| US 11,572,373 | Maytansinoid-Based Drug Delivery Systems Formerly held In force · High confidence | In force | High confidence | |
| US 8,962,604 | Use of a Hydroximic Acid Halide Derivative in the Treatment of Neurodegenerative Diseases Formerly held Lapsed on the fee record Ended Feb 24, 2023 · Medium confidence | Lapsed on the fee record | Ended Feb 24, 2023 | Medium confidence |
| US 7,691,849 | Carboxamidine derivatives and their use in the treatment of vascular diseases Formerly held Lapsed on the fee record Ended Apr 6, 2022 · USPTO record | Lapsed on the fee record | Ended Apr 6, 2022 | USPTO record |
| US 7,126,002 | Pyridine-1-oxide derivative, and process for its transformation into pharmaceutically effective compounds Formerly held Term ended Term ended Oct 14, 2021 · USPTO record | Term ended | Term ended Oct 14, 2021 | USPTO record |
| US 7,550,457 | Pharmaceutically effective compounds Formerly held Lapsed on the fee record Ended Jun 23, 2021 · USPTO record | Lapsed on the fee record | Ended Jun 23, 2021 | USPTO record |
| US 6,384,029 | Optically active pyridyl-4h-1,2,4-oxdadiazine derivative and its use in the treatment of vascular diseases Formerly held Term ended Term ended May 15, 2021 · USPTO record | Term ended | Term ended May 15, 2021 | USPTO record |
| US 7,384,936 | Carboxamidine derivatives and their use in the treatment of vascular diseases Formerly held Lapsed on the fee record Ended Jun 10, 2020 · USPTO record | Lapsed on the fee record | Ended Jun 10, 2020 | USPTO record |